Novartis Conducts Fluvirin Recovery

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Liverpool, UK (Oct. 20)-Novartis Vaccines and Diagnostics Limited is recovering two lots totaling 500,000 doses of its ?Fluvirin? influenza virus vaccine after reports that the product had been received from distributor Cardinal Health Care in either a frozen state or below the required storage temperature range of 35?46 degrees F.

Liverpool, UK (Oct. 20)-Novartis Vaccines and Diagnostics Limited (www.novartis.com) is recovering two lots totaling 500,000 doses of its “Fluvirin” influenza virus vaccine after reports that the product had been received from distributor Cardinal Health Care (LaVergne, TN, www.cardinalhealth.com) in either a frozen state or below the required storage temperature range of 35­–46 degrees F.

The 5-mL multidose vials containing the “Chiron Vaccines” label have lot numbers 71209 and 71210 (both with an expiration date of June 30, 2007). They were shipped under a contract with the Centers for Disease Control and distributed between Oct. 11 and Oct. 17, 2006. Novartis is conducting the recovery solely as a precautionary action. Freezing inactivates the influenza vaccine but its administration does not pose a risk to patient safety, according the Recovery Notice posted by the US Food and Drug Administration (Rockville, MD, www.fda.gov). Meanwhile, Cardinal Health is reportedly conducting its own investigation into how the product became frozen.

Novartis plans to ship new vaccines through a different distributor in early November.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content